Predictors of seroconversion after coronavirus disease 2019 vaccination
- 28 May 2022
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 129 (2) , 189-193
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K08AI141765)
- NCATS
This publication has 39 references indexed in Scilit:
- Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021Eurosurveillance, 2021
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- Coronavirus disease 2019 in patients with inborn errors of immunity: An international studyJournal of Allergy and Clinical Immunology, 2021
- Looking beyond COVID-19 vaccine phase 3 trialsNature Medicine, 2021
- COVID-19 and comorbidities: Deleterious impact on infected patientsJournal of Infection and Public Health, 2020
- Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosusLupus, 2020
- Association Between Male Sex and Outcomes of Coronavirus Disease 2019 (COVID-19)—A Danish Nationwide, Register-based StudyClinical Infectious Diseases, 2020
- Clinical outcomes of COVID-19 in elderly male patients2020
- Age and Influenza-Specific Pre-Vaccination Antibodies Strongly Affect Influenza Vaccine Responses in the Icelandic Population whereas Disease and Medication Have Small EffectsFrontiers in Immunology, 2018
- Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score WorkMedical Care, 2015